1. Home
  2. VCSA vs ACXP Comparison

VCSA vs ACXP Comparison

Compare VCSA & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VCSA
  • ACXP
  • Stock Information
  • Founded
  • VCSA 2009
  • ACXP 2017
  • Country
  • VCSA United States
  • ACXP United States
  • Employees
  • VCSA N/A
  • ACXP N/A
  • Industry
  • VCSA Computer Software: Prepackaged Software
  • ACXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • VCSA Technology
  • ACXP Health Care
  • Exchange
  • VCSA Nasdaq
  • ACXP Nasdaq
  • Market Cap
  • VCSA 38.6M
  • ACXP 31.4M
  • IPO Year
  • VCSA N/A
  • ACXP 2021
  • Fundamental
  • Price
  • VCSA $2.96
  • ACXP $1.34
  • Analyst Decision
  • VCSA Buy
  • ACXP Strong Buy
  • Analyst Count
  • VCSA 4
  • ACXP 1
  • Target Price
  • VCSA $6.08
  • ACXP $12.00
  • AVG Volume (30 Days)
  • VCSA 64.6K
  • ACXP 97.1K
  • Earning Date
  • VCSA 11-07-2024
  • ACXP 11-12-2024
  • Dividend Yield
  • VCSA N/A
  • ACXP N/A
  • EPS Growth
  • VCSA N/A
  • ACXP N/A
  • EPS
  • VCSA N/A
  • ACXP N/A
  • Revenue
  • VCSA $949,936,000.00
  • ACXP N/A
  • Revenue This Year
  • VCSA N/A
  • ACXP N/A
  • Revenue Next Year
  • VCSA N/A
  • ACXP N/A
  • P/E Ratio
  • VCSA N/A
  • ACXP N/A
  • Revenue Growth
  • VCSA N/A
  • ACXP N/A
  • 52 Week Low
  • VCSA $2.07
  • ACXP $1.18
  • 52 Week High
  • VCSA $11.70
  • ACXP $5.28
  • Technical
  • Relative Strength Index (RSI)
  • VCSA 52.58
  • ACXP 17.48
  • Support Level
  • VCSA $2.67
  • ACXP $1.18
  • Resistance Level
  • VCSA $3.46
  • ACXP $1.73
  • Average True Range (ATR)
  • VCSA 0.28
  • ACXP 0.12
  • MACD
  • VCSA -0.00
  • ACXP -0.05
  • Stochastic Oscillator
  • VCSA 47.11
  • ACXP 22.22

About VCSA Vacasa Inc.

Vacasa Inc is a vacation rental management platform in North America, transforming the vacation rental experience by integrating purpose-built technology with expert local and national teams.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

Share on Social Networks: